Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 2/20 | 0.37 |
| ▸ | FNTB | P49356 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | MARS1 | P56192 | 1/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.35 |
| ▸ | RBBP9 | O75884 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6775938 | 0.85 | PTGDR2 (0.48) | FNTAFNTBTDP1PGGT1B | |
| SCHEMBL6774858 | 0.81 | FNTA (0.54) | FNTAFNTBTDP1PGGT1B | |
| SCHEMBL6623986 | 0.80 | FNTA (0.52) | FNTAFNTBTDP1PGGT1B | |
| SCHEMBL6623995 | 0.80 | FNTA (0.52) | FNTAFNTBTDP1PGGT1B | |
| SCHEMBL6672023 | 0.79 | NPC1 (0.44) | FNTAFNTBTDP1PGGT1B | |
| SCHEMBL6624888 | 0.78 | FNTA (0.44) | FNTAFNTBTDP1MARS1PGGT1B | |
| SCHEMBL8608789 | 0.77 | FNTA (0.44) | FNTAFNTBTDP1MARS1PGGT1B | |
| SCHEMBL6777898 | 0.76 | PTGS2 (0.39) | FNTAFNTBTDP1MARS1PGGT1B | |
| SCHEMBL6776515 | 0.76 | FNTA (0.39) | FNTAFNTBTDP1MARS1PGGT1B | |
| SCHEMBL6775076 | 0.75 | FNTA (0.38) | FNTAFNTBTDP1MARS1PGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0986384-A4 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6693123-B2 | (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA | UNIVERSITY OF PITTSBURGH | 2004-02-17 | — | — | US | disclosed |
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | UNIVERSITY OF PITTSBURGH (US) | 2002-12-19 | — | — | US | disclosed |
| US-6310095-B1 | INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE | UNIVERSITY OF PITTSBURGH | 2001-10-30 | — | — | US | disclosed |
| US-6221865-B1 | INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND PROTEIN GERANYLGERANYLTRANSFERASE. | UNIVERSITY OF PITTSBURGH | 2001-04-24 | — | — | US | disclosed |
| US-6204293-B1 | INHIBITING POST-TRANSLATIONAL MODIFICATION OF THE ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE, PROTEIN GERANYLGERANYLTRANSFERASE, OR BOTH | UNIVERSITY OF PITTSBURGH | 2001-03-20 | — | — | US | disclosed |
| EP-0986384-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998050029-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | LANCL1, FNTB, DHCR7 | PLA2G7 545/4885FNTA 20/4885FNTB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.